There are several potential targets for pharmacological intervention aimed at modifying Parkinson's disease, including addressing neuroinflammation, mitochondrial dysfunction, oxidative stress, calcium channel activity, LRRK2 kinase activity, α-synuclein accumulation, aggregation, and cell-to-cell transmission. This evidence concerns the gene LRRK2 and Parkinson disease.